Ramucirumab is under clinical development by Eli Lilly and Co and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Ramucirumab’s likelihood of approval (LoA) and phase transition for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) took place on 12 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ramucirumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Ramucirumab overview

Ramucirumab (Cyramza) is an antineoplastic agent. It is formulated as the solution for injection for intravenous route o administration. Cyramza as a single agent, or in combination with paclitaxel, is indicated for the treatment of patients with advanced  or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine-or platinum-containing chemotherapy, in combination with docetaxel, is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy, in combination with FOLFIRI (irinotecan, folinic acid, and 5 -fluorouracil), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine, and as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥400 ng/mL and have been previously treated with sorafenib. Cyramza in combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations.

The drug candidate is under development for the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT), hepatocellular carcinoma, malignant mesothelioma, refractory/relapsed synovial sarcoma, pancreatic adenocarcinoma, adenocarcinoma of the gastroesophageal junction, bladder cancer, urethral cancer, squamous non-small cell lung cancer, metastatic colorectal cancer, progressive carcinoid tumors, squamous cell carcinoma of the esophagus, pancreatic neuroendocrine tumor, gallbladder cancer, small-cell lung cancer and metastatic biliary tract cancer, metastatic thymic carcinoma, gastroesophageal junction region (GEJ) cancer, pediatric solid tumors including CNS, non-CNS tumors. The drug candidate was also under development for the treatment of HER2 negative metastatic breast cancer and gastric cancer as first-line therapy, fallopian tube cancer, peritoneal tumor, epithelial ovarian cancer, metastatic hormone refractory (castration-resistant, androgen-independent) prostate cancer, metastatic melanoma, bladder cancer, metastatic transitional cell cancer (urothelial cell cancer) including bladder cancer, urethral cancer, ureter cancer, recurrent glioblastoma multiforme (GBM), mantle cell lymphoma,  HER2 positive metastatic breast cancer as second-line therapy, metastatic renal cell carcinoma, signet ring cell squamous cell carcinoma. It is administered through subcutaneous route.

Eli Lilly and Co overview

Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.

Quick View Ramucirumab LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Ramucirumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.